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Quantitative Phosphoproteomics Unravels
Biased Phosphorylation of Serotonin 2A
Receptor at Ser280 by Hallucinogenic versus
Nonhallucinogenic Agonists*□S
Samah Karaki‡§¶, Carine Becamel‡§¶, Samy Murat‡‡¶, Clotilde Mannoury la Cour**,
Mark J. Millan**, Laurent Pre´zeau‡§¶, Joe¨l Bockaert‡§¶, Philippe Marin‡§¶§§,
and Franck Vandermoere‡§¶‡‡§§
The serotonin 5-HT2A receptor is a primary target of psy-
chedelic hallucinogens such as lysergic acid diethyl-
amine, mescaline, and psilocybin, which reproduce some
of the core symptoms of schizophrenia. An incompletely
resolved paradox is that only some 5-HT2A receptor ago-
nists exhibit hallucinogenic activity, whereas structurally
related agonists with comparable affinity and activity lack
such a psychoactive activity. Using a strategy combining
stable isotope labeling by amino acids in cell culture with
enrichment in phosphorylated peptides by means of hy-
drophilic interaction liquid chromatography followed by
immobilized metal affinity chromatography, we compared
the phosphoproteome in HEK-293 cells transiently express-
ing the 5-HT2A receptor and exposed to either vehicle or the
synthetic hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-
aminopropane (DOI) or the nonhallucinogenic 5-HT2A ago-
nist lisuride. Among the 5995 identified phosphorylated
peptides, 16 sites were differentially phosphorylated upon
exposure of cells to DOI versus lisuride. These include a
serine (Ser280) located in the third intracellular loop of the
5-HT2A receptor, a region important for its desensitiza-
tion. The specific phosphorylation of Ser280 by hallucino-
gens was further validated by quantitative mass spec-
trometry analysis of immunopurified receptor digests and
by Western blotting using a phosphosite specific anti-
body. The administration of DOI, but not of lisuride, to
mice, enhanced the phosphorylation of 5-HT2A receptors
at Ser280 in the prefrontal cortex. Moreover, hallucinogens
induced a less pronounced desensitization of receptor-
operated signaling in HEK-293 cells and neurons than did
nonhallucinogenic agonists. The mutation of Ser280 to as-
partic acid (to mimic phosphorylation) reduced receptor
desensitization by nonhallucinogenic agonists, whereas
its mutation to alanine increased the ability of hallucino-
gens to desensitize the receptor. This study reveals a
biased phosphorylation of the 5-HT2A receptor in re-
sponse to hallucinogenic versus nonhallucinogenic ago-
nists, which underlies their distinct capacity to desensi-
tize the receptor. Molecular & Cellular Proteomics 13:
10.1074/mcp.M113.036558, 1273–1285, 2014.
Among the G Protein-Coupled Receptors (GPCRs)1 acti-
vated by serotonin (5-hydroxytryptamine, 5-HT), the 5-HT2A
receptor continues to attract particular attention in view of its
broad physiological role and implication in the actions of
numerous psychotropic agents (1, 2). It is a primary target of
widely used atypical antipsychotics such as clozapine, risperi-
done, and olanzapine, which act as antagonists or inverse
agonists (1, 3). The activation of 5-HT2A receptors expressed
in the prefrontal cortex has also been implicated in the psy-
cho-mimetic effects of psychedelic hallucinogens, such as
lysergic acid diethylamide (LSD), mescaline, and psilocybin,
which are often used to model positive symptoms of schizo-
phrenia (4–8). However, these psychoactive effects are not
reproduced by structurally-related agonists, such as ergota-
mine and the anti-Parkinson agent lisuride, despite the fact
that they exhibit comparable affinities and efficacies at 5-HT2A
receptors (7, 9). This paradox was partially resolved by the
demonstration that hallucinogens induce a specific transcrip-
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tomic signature because of the specific engagement of a
Pertussis toxin-sensitive Gi/o/Src signaling pathway which is
not activated by nonhallucinogenic agonists (7, 8). These
findings suggest that hallucinogenic and nonhallucinogenic
agonists induce different conformational states of the 5-HT2A
receptor, and represent a striking example of functional se-
lectivity that translates into contrasting pattern of mice behav-
ior: induction of head-twitches by hallucinogenic but not by
nonhallucinogenic agonists (9).
The differential influence of hallucinogenic versus nonhallu-
cinogenic agonists on signaling pathways suggests that they
trigger contrasting patterns of protein phosphorylation. To
address this issue, we employed a quantitative phosphopro-
teomics strategy to directly compare the phosphoproteomes
generated in HEK-293 cells by the synthetic hallucinogen
1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) and
the nonhallucinogenic 5-HT2A agonist lisuride. We found that
DOI, but not lisuride, induced the phosphorylation of a serine
residue (Ser280) located in the third intracellular loop of the
receptor itself. The hallucinogen-specific phosphorylation of
this residue was further validated in vitro and in vivo by using
a phosphosite-specific antibody. These findings were fol-
lowed by a series of experiments to determine the impact of
Ser280 phosphorylation upon receptor desensitization and
internalization.
EXPERIMENTAL PROCEDURES
Materials—Human Embryonic Kidney-293 (HEK-293) cells were
from the European Collection of Cell Cultures, culture media from
Invitrogen (Carlsbad, CA). Lisuride maleate was from Santa Cruz
Biotechnologies (Santa Cruz, CA). All other chemicals were from
Sigma Aldrich. Isotope-labeled amino acids for SILAC experiments
were from Eurisotop (Saint Aubin, France).
The rabbit anti-phospho-Thr202/Tyr204-Erk1,2, and anti-total Erk1,2
antibodies were from Cell Signaling Technology (Danvers, MA), the
rabbit anti-Hemagglutinin (HA) antibody from Zymed Laboratories
Inc. (South San Francisco, CA), the rabbit anti-GFP antibody from
Roche Diagnostics, the rabbit anti-5-HT2A receptor antibody from
Immunostar (Hudson, MI) and the mouse anti-HA antibody conju-
gated to agarose beads from Sigma Aldrich. The anti-phosphoSer280-
5-HT2A receptor antibody was generated by immunizing rabbits with
the synthetic GTRAKLApSFSFLC peptide coupled to Keyhole Lim-
pet Hemocyanin (KLH, Eurogentec, Liege, Belgium).
The construct encoding the HA-tagged 5-HT2A receptor was de-
scribed elsewhere (10). Following PCR amplification, the receptor
cDNA was subcloned into the bicistronic plasmid pIRES2-EGFP
(Clontech, Mountain View, CA) using the XhoI/BamhI restriction sites.
This construct was transferred to pSinRep5 plasmid for Sindbis virus
production (11). Plasmids encoding HA-tagged 5-HT2A receptor mu-
tants (S280A and S280D) were generated using the Quick Change
mutagenesis kit (Stratagene, La Jolla, CA). All constructs were con-
firmed by DNA sequencing.
Cell Cultures—HEK-293 cells, grown in Dulbecco’s modified Ea-
gle’s medium (DMEM) supplemented with 10% dialyzed, heat-inac-
tivated fetal calf serum and antibiotics, were transfected at 40–50%
confluence using polyethyleneimine (PEI, Sigma-Aldrich), as previ-
ously described (12), and used 48 h after transfection. For stable
isotope labeling by amino acids in cell culture (SILAC) experiments
(13), cells were maintained for 2 weeks in DMEM deficient in lysine
and arginine, supplemented with 10% dialyzed serum and either
L-lysine/L-arginine for light label (K0R0, L) or L-Lysine-2HCl (2H4,
96–98%)/L-Arginine-HCl (13C6, 99%) for semi-heavy label (K4R6, M)
or L-Lysine-2HCl (13C6, 99%;
15N2, 99%)/L-Arginine-HCl (
13C6, 99%;
15N4, 99%) for heavy label (K8R10, H) (percentages represent the
isotopic purity of the labeled amino acids). Under these conditions,
analysis of semi-heavy amino acid incorporation at the protein level
indicated a median ratio of 93% (first quartile at 88%, third quartile at
95%). A similar distribution was observed for the incorporation of the
heavy amino acids.
Primary cultures of cortical neurons were prepared as described
previously (14). Briefly, dissociated cells from the cerebral cortex of 17
day-old Swiss mouse embryos were plated on 6- or 96-well plates
coated successively with poly-l-ornithine (mol. Wt.  40,000; 15
g/ml) and 10% fetal calf serum  1 g/ml laminin. The culture
medium included a 1:1 mixture of DMEM and F-12 nutrient supple-
mented with 33 mM glucose, 2 mM glutamine, 13 mM NaHCO3, 5 mM
HEPES buffer, pH 7.4, 5 IU/ml (5 mg/ml) penicillin-streptomycin, and
a mixture of salt and hormones containing 100 g/ml transferin, 25
g/ml insulin, 20 nM progesterone, 60 nM putrescine, and 30 nM
Na2SeO3. Cultures were infected 5 days after seeding with the Sind-
bis virus expressing HA-tagged 5-HT2A receptor and were used 7
days after seeding. At this stage, they were shown to contain at least
95% of neurons (14).
Global Quantitative Phosphoproteomics Analyses—HEK-293 cells
grown in SILAC media and transiently expressing 5-HT2A receptors
were serum-starved for 4 h and challenged for 15 min with either
vehicle (L), or lisuride (1 M, M), or DOI (1 M, H). Cells were lysed in
0.5 ml of ice-cold lysis buffer (50 mM Tris-HCl, pH 7.5, 1 mM EGTA,
1% Triton X-100, 1 mM sodium orthovanadate, 50 mM sodium fluo-
ride, 5 mM sodium pyrophosphate, 0.27 M sucrose, 1 mM DTT). Cell
lysates were clarified by centrifugation at 15,000  g (20 min at 4 °C)
and protein concentration was determined using the Bradford re-
agent. Equal amounts of proteins (3 mg) from each condition were
mixed, reduced with 10 mM DTT, alkylated with 50 mM iodoacetamide
and precipitated on ice with trichloroacetic acid (25%, 20 min) before
their digestion with trypsin (1/200, w/w) in 2 M urea, 25 mM triethyl-
ammonium bicarbonate pH 7.8. Digests were acidified in 1% TFA,
desalted on a 1-g Sep-Pak cartridge (Waters, Milford, MA), and
subjected to hydrophilic interaction liquid chromatography (HILIC)
using a 4.6  250-mm TSKgel Amide-80 5-m particle column
(Tosoh Biosciences) and an Alliance e2695 HPLC system (Waters), as
previously described (15). Nine mg of peptides were loaded in 80%
solvent B (100% acetonitrile with 0.1% TFA). Solvent A consisted of
0.1% TFA in water. Peptides were eluted with a gradient consisting of
80% B held for 5 min followed by 80% B to 60% B in 40 min and
finally 0% B for 5 min. Fourteen fractions were collected throughout
the gradient and further enriched in phosphorylated peptides by
immobilized metal affinity chromatography (IMAC) (15).
HILIC fractions were dried and resuspended in 25% acetonitrile/
0.1% TFA and incubated for 3 h with 8 l of Phos-Select beads
(Sigma Aldrich) under agitation. Beads were rinsed twice with 100 l
of 25% acetonitrile/0.1% TFA and loaded on a microC18 ZipTip
(Millipore). Phosphorylated peptides were then eluted in two steps
with 30 l of 0.4 M NH4OH and then with 30 l of 50% acetonitrile.
They were analyzed by nano-flow HPLC-nanoelectrospray ionization
using a LTQ Orbitrap Velos mass spectrometer coupled to an Ulti-
mate 3000 HPLC (Thermo Fisher Scientific). Desalting and precon-
centration of samples were performed on-line on a Pepmap® precol-
umn (0.3 mm  10 mm, Thermo Fisher Scientific, Courtaboeuf,
France). A gradient consisting of 2–40% buffer B (3–33 min), 40–80%
B (33–34 min), 80–0% B (49–50 min), and equilibrated for 20 min in
0% B (50–70 min) was used to elute peptides at 300 nL/min from a
Pepmap® capillary (0.075 mm  150 mm) reversed-phase column
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(LC Packings). Mass spectra were acquired using a top-10 collision-
induced dissociation (CID) data-dependent acquisition (DDA)
method. The LTQ-Orbitrap was programmed to perform a Fourier
transform (FT) full scan (60,000 resolution) on 400–1400 Th mass
range with the top ten ions from each scan selected for LTQ-MS/MS
with multistage activation on the neutral loss of 24.49, 32.66, and
48.99 Th. FT spectra were internally calibrated using a single lock
mass (445.1200 Th). Target ion numbers were 500,000 for FT full scan
on the Orbitrap and 10,000 MSn on the LTQ.
The raw MS data were analyzed using the MaxQuant/Andromeda
software (v. 1.2.2.5) (16) with a false discovery rate of less than 0.01
for peptides and phosphosites and a minimum peptide length of six
amino acids. The mass accuracy of the precursor ions was improved
by retention time-dependent mass recalibration. Andromeda was
used to search the top eight per 100 Da peak lists against the human
complete proteome set database (http://www.uniprot.org/uniprot/
?query  organism:9606keyword:1185) downloaded on February
22, 2012 (65,835 protein entries), combined with 248 frequently ob-
served contaminants as well as reversed versions of all sequences.
This version of the database contains both reviewed sequences from
UniProtKB/Swiss-Prot and unreviewed sequences from UniProtKB/
TrEMBL. Enzyme specificity was set to trypsin, additionally allowing
cleavage N-terminal to proline and up to two missed cleavages. The
search included cysteine carbamidomethylation as a fixed modifica-
tion, protein N-terminal acetylation, oxidation of methionine and
phosphorylation of Ser, Thr, and Tyr as variable modifications. Pep-
tide identification was based on a search with a mass deviation of the
precursor ion up to 7 ppm after recalibration, and the allowed frag-
ment mass deviation was set to 0.5 Da. Identifications across different
replicates and adjacent fractions was performed using the “match
between runs” MaxQuant option with a 3 min time window. Quanti-
fication of SILAC triplex signals was performed by MaxQuant with
standard settings. The phosphoSTY.txt file generated by MaxQuant
was uploaded onto Perseus software (v. 1.2.0.17) to calculate B
significance of phosphopeptide ratios in each of the three biological
replicates (16). The new table was then uploaded onto the R environ-
ment in order to plot log H/M ratios against log M/L ratios and
color-display the B significance count (p  0.05) for each quantified
phosphopeptide.
Targeted Analysis of 5-HT2A Receptor Phosphorylation in HEK-293
Cells—HEK-293 cells transiently expressing HA-tagged 5-HT2A re-
ceptors were lysed in 50 mM Tris-HCl, pH 7.5, 1 mM EGTA, 1% Triton
X-100, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 5 mM
sodium pyrophosphate, 0.27 M sucrose, 1 mM DTT, and a protease
inhibitor mixture (Roche). Samples were centrifuged at 15,000  g for
30 min at 4 °C. Solubilized 5-HT2A receptors were immunoprecipi-
tated with the agarose-conjugated anti-HA antibody (Sigma Aldrich).
Immunoprecipitated HA-5-HT2A receptors were resolved by SDS-
PAGE. Gel bands containing the receptor were excised and digested
with trypsin (500 ng per condition). Peptides were analyzed by nano-
LC-FT-MS/MS, top six per 30 Da windows peak lists were extracted
using MSconvert 3.0 and searched with Mascot 2.4 against the same
human Complete Proteome Set database, with phosphorylation of
Ser, Thr, and Tyr as variable modifications, 7 ppm precursor mass
tolerance, 0.5 Da fragment mass tolerance and trypsin/P digestion.
MS2 spectra matching phosphorylated peptides with ion score over
15 were inspected using Prophossi software (17) for automatic an-
notation of unique transitions that pinpoint the position of phosphor-
ylation sites. Ion signals corresponding to phosphorylated peptides
were quantified from the maximal intensities measured in their ion
chromatograms manually extracted using Qual browser v2.1 (Thermo
Fisher Scientific) with a tolerance of 5 ppm for mass deviation, and
normalized to signals of their nonphosphorylated counterparts. Ser280
phosphorylation of immunoprecipitated receptors was also analyzed
by Western blotting using the phosphosite specific antibody.
Western Blotting—Proteins, resolved onto 10% polyacrylamide
gels, were transferred to Hybond C nitrocellulose membranes (GE
Healthcare). Membranes were immunoblotted with primary antibod-
ies (anti phospho-Ser280 5-HT2A receptor, 1:300; anti phospho-Thr
202/
Tyr204-Erk1,2, 1:1000; anti Erk1,2, 1:1000; anti-HA, 1:1000; Anti-GFP,
1:1000; anti-RSK2, 1:1000) and then with either anti-mouse or anti-
rabbit horseradish peroxidase-conjugated secondary antibodies (1:
3000, GE Healthcare). Immunoreactivity was detected with an en-
hanced chemiluminescence method (ECLTM plus detection reagent,
GE Healthcare) and immunoreactive bands were quantified by den-
sitometry using the ImageJ software. In protein phosphorylation anal-
yses, the amount of each phosphoprotein was normalized to the
amount of the corresponding total protein detected in the sample.
Analysis of Ser280 Phosphorylation in Mice Prefrontal Cortex—
Experiments were performed on wild type or 5-HT2A receptor-defi-
cient mice (8) and conformed to European ethics standards (86/609-
EEC) and to decrees of the French National Ethics Committee (N°
87/848) for the care and use of laboratory animals. Mice (30 g) were
injected intraperitoneal with either vehicle (5% DMSO/5% Tween 80)
or DOI or lisuride (10 mg/kg each). Thirty min after the onset of the
treatment, mice were anesthetized with pentobarbital (100 mg/kg
intraperitoneal, Ceva SA) and rapidly perfused transcardiacally with
fixative solution containing 4%w/v paraformaldehyde in 0.1 M sodium
phosphate buffer (pH 7.5) containing NaF (100 mM) and sodium
orthovanadate (1 mM). Brains were post-fixed for 48 h in the same
solution and stored at 4 °C. Fifty micrometers-thick sections were cut
with a vibratome (Leica), permeabilized with 0.2% Triton X-100 in Tris
buffer saline (TBS) for 20 min, saturated for 1 h with 10% goat serum
in TBS containing 0.03% Triton X-100 and incubated for 48 h at 4 °C
with primary antibodies (anti phospho-Ser280 5HT2A receptor, 1:100
or anti 5-HT2A receptor, 1:500) in TBS. After four washes, they were
incubated for 1 h with an Alexa Fluor® 488-conjugated anti-rabbit
antibody (1:1000, Invitrogen) in TBS. Immunofluorescent staining was
observed with a Zeiss Axioimager Z1 microscope equipped with
apotome. Images were acquired using the Axiovision 4.8 software
driving an AxioCam MRm CCD camera (Carl Zeiss Microimaging).
Inositol Phosphate Production—Inositol phosphate production was
analyzed as previously described (18).
Immunocytochemistry and Fluorescent Microscopy—HEK-293
cells transiently expressing HA-tagged 5-HT2A receptors and grown
on glass cover-slips were incubated with the rabbit anti HA antibody
(1/500, 30 min at 10 °C) and then with drugs for 1 h at 37 °C. Cells
were fixed in 4% (w/v) paraformaldehyde, 4% sucrose in PBS for 20
min, quenched 4 times 10 min with PBS containing 4% sucrose and
0.1 M glycine, and incubated for 60 min at 4 °C with an Alexa Fluor®
594-coupled anti-rabbit antibody (1:1000 in PBS supplemented with
2% goat serum, Invitrogen) to label cell surface receptors. They were
then rinsed three times PBS containing 2% goat serum, permeabi-
lized with 0.2% (w/v) Triton X-100 in PBS containing 2% goat serum
for 15 min and incubated for 30 min at 4 °C with the Alexa Fluor®
488-coupled anti-rabbit antibody (1:1000 in PBS supplemented with
2% goat serum, 0.05% Triton X-100) to label internalized receptors.
After three washes, coverslips were mounted on glass slides in
Mowiol® 4.88 (Calbiochem). Series of optical sections were collected
with a Zeiss Axioimager Z1 microscope equipped with apotome.
Images were acquired using the Axiovision 4.8 software driving an
AxioCam MRm CCD camera (Carl Zeiss Microimaging).
ELISA—Quantification of receptor cell surface expression was per-
formed by ELISA under nonpermeabilized conditions as previously
described (18).
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RESULTS
Phosphoproteome Changes Elicited by DOI and Lisuride in
HEK-293 Cells—To directly compare the phosphorylation
patterns generated upon 5-HT2A receptor stimulation by a
hallucinogenic (DOI) and by a nonhallucinogenic (lisuride)
agonist, we used the SILAC technology under three experi-
mental conditions: light condition (vehicle-treated cells), semi-
heavy label (lisuride-treated cells), and heavy label (DOI-
treated cells). As cultured neurons do not divide in vitro, a
complete SILAC labeling prerequisite for unbiased quantifica-
tion could not be achieved in these cultures. Therefore, we
performed our phosphoproteomics screen in HEK-293 cells
transiently expressing 5-HT2A receptors. We first examined
whether this model recapitulates the biased signaling at
5-HT2A receptors initially described in neurons, i.e. specific
activation of Gi/o signaling by hallucinogens (7). Exposure of
cells to DOI or LSD induced comparable stimulation of inositol
phosphate production and Extracellular-regulated kinase
(Erk)1,2 phosphorylation to those elicited by two nonhalluci-
nogenic agonists, lisuride and ergotamine, though activation
of PLC by DOI and Erk1,2 phosphorylation elicited by LSD
were slightly more pronounced (supplemental Figs. S1A and
S2A). Pre-treating cells with Pertussis toxin (PTX) decreased
PLC activation induced by DOI and LSD (supplemental Fig.
S1B, S1C) and abolished Erk1,2 phosphorylation induced by
both hallucinogens (supplemental Fig. S2A), whereas PTX
treatment did not affect the lisuride and ergotamine re-
sponses (Figs. S1D, S1E, and S2A). PTX likewise prevented
Erk1,2 phosphorylation induced by DOI and LSD without af-
fecting lisuride and ergotamine responses in primary cultured
cortical neurons (supplemental Fig. S2B). These observations
indicate that, similarly to the observations in neurons, hallu-
cinogens selectively engage Gi/o-operated signaling in HEK-
293 cells, whereas nonhallucinogenic agonists do not.
After a 15-min stimulation of stable isotope-labeled HEK-
293 cells with either vehicle or DOI or lisuride, cells were
harvested and 1:1:1 mixtures of differentially labeled samples
were digested with trypsin and phosphopeptides were en-
riched by HILIC followed by IMAC. Analysis of phosphopep-
tide-enriched fractions by nano-LC-FT-MS/MS identified
5995 phosphorylated peptides with a false discovery rate of
1%. A total of 3349 phosphopeptides were robustly quantified
in at least two out of the three biological replicates. As shown
in Fig. 1A, the majority of them did not exhibit significant
changes in abundance, assessed by statistical significance B
(16), upon 5-HT2A receptor stimulation by DOI or lisuride
(agonist/vehicle ratios 1). Only 30 phosphorylated peptides
were significantly regulated by DOI versus vehicle and 24
following lisuride treatment (supplemental Table S1). Most
importantly, 16 phosphopeptides were significantly different
in abundance between DOI and lisuride-treated cells and 10
of them were significantly regulated by DOI, compared with
vehicle (supplemental Table S1).
Hallucinogens but Not Nonhallucinogenic Agonists Induce
5-HT2A Receptor Phosphorylation at Ser
280 In Vitro and In
Vivo—Among the phosphopeptides exhibiting the highest dif-
ferences in abundance between DOI and lisuride-treated
cells, we identified a peptide located in the third intracellular
(i3) loop of the receptor itself and phosphorylated on three Ser
residues (278LApSFSFIPQSpSISpSEK293, supplemental Table
S1) corresponding to Ser280, Ser288, and Ser291 in the entire
receptor sequence. To further analyze 5-HT2A receptor phos-
phorylation pattern and to confirm its differential phosphory-
lation by hallucinogenic and nonhallucinogenic agonists, re-
ceptors originating from vehicle- or agonist-treated cells were
purified by immunoprecipitation and digested with trypsin.
LC-MS/MS analysis of receptor digests identified several
phosphorylated forms of the same peptide located in the
receptor i3 loop (LASFSFIPQSSISSEK) (Table I). MS2 spectra
matching phosphorylated peptides were inspected using Pro-
phossi software (17) for automatic annotation of unique tran-
sitions that pinpoint the position of phosphorylation sites
(supplemental Fig. S3). In addition to a uniquemonophosphor-
ylated form (phosphorylated at Ser280), various doubly and
triply phosphorylated forms corresponding to phosphoryla-
tion on Ser280 and either on Ser283 or Ser287 or Ser288 or
Ser290 or Ser291 or on two of these residues) were also de-
tected (Table I). Moreover, quantitative analysis of the corre-
sponding ion signals from extracted ion chromatograms
showed that the monophosphorylated peptide exhibited the
highest relative abundance and that it was up-regulated by
DOI or LSD exposure but not by lisuride or ergotamine (Table
I, Fig. 1B, and supplemental Fig. S4). Though less abundant,
the other multi-phosphorylated forms were likewise specifi-
cally up-regulated by hallucinogenic agonists (Table I and
supplemental Fig. S4). In addition, these analyses identified
another cluster of phosphorylated serines (Ser298 and Ser305)
in a different receptor i3 loop peptide (298SIHREPGSYTGR309)
(Table I and supplemental Fig. S4). Both mono-phosphory-
lated (at Ser298) and doubly phosphorylated forms of this
peptide were detected. However, the basal level of phosphor-
ylation of these residues was weakly increased by both hal-
lucinogens and nonhallucinogenic agonists (Table I and sup-
plemental Fig. S4).
Given the apparent higher stoichiometry of Ser280 phos-
phorylation, compared with the phosphorylation of other res-
idues, and the specific induction of its phosphorylation by
hallucinogens, we produced a rabbit antibody against a phos-
phopeptide encompassing phosphorylated Ser280. We first
validated the specificity of this antibody for the phosphory-
lated site by Western blotting using transfected HEK-293
cells. Although no immunoreactive signal was detected in
blots from nontransfected cells, a clear signal was observed
at the expected receptor size in blots obtained from cells
expressing 5-HT2A receptor, and this immunoreactivity signal
increased upon cell exposure to DOI or LSD, but not to
ergotamine or lisuride (Fig. 2A). In contrast, DOI exposure did
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not increase the immunoreactive signal in blots obtained from
cells expressing 5-HT2A receptors mutated on Ser
280 (S280A,
Fig. 2B and supplemental Fig. S5). Moreover, the signal ob-
served in the absence of agonist treatment was lower in cells
expressing mutant 5-HT2A receptors than in cells expressing
wild type receptors (Fig. 2B). Collectively, these findings dem-
onstrate a strong specificity of this antibody for phosphoryl-
ated Ser280 and further confirm the unique capacity of hallu-
FIG. 1. Hallucinogenic and nonhallucinogenic agonists differentially phosphorylate 5-HT2A receptor at Ser
280. A, Results of the
large-scale quantitative phosphoproteomic analysis comparing the phosphorylation events triggered by DOI and lisuride (1 M each, 15 min)
in HEK-293 cells transiently expressing 5-HT2A receptors. The x axis represents the relative abundance (expressed in log10 of the ratio) of each
of the 3349 quantified phosphopeptides in lisuride versus vehicle-treated cells, the y axis their relative abundance in DOI versus vehicle-treated
cells. B, HEK-293 cells transiently expressing HA-tagged 5-HT2A receptors were challenged for 15 min with vehicle or 1 M of either LSD or
DOI or lisuride, or ergotamine. Receptors were immunoprecipitated with the agarose bead-conjugated anti HA antibody, digested with trypsin
and phosphorylated peptides were analyzed by MS/MS. The data illustrated show representative extracted ion chromatograms of the
LApSFSFIPQSSISSEK peptide phosphorylated on a serine corresponding to Ser280 in the entire receptor sequence. Two other independent
experiments performed on different sets of cultured cells yielded similar results. The histogram represents the means  S.E. of ion signal
intensities of the LApSFSFIPQSSISSEK peptide obtained in the three experiments. * p  0.05 versus vehicle-treated cells.
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cinogens to promote phosphorylation of this residue,
compared with nonhallucinogenic agonists.
To explore whether biased 5-HT2A receptor phosphoryla-
tion occurs in vivo, we injected mice with either DOI or lisuride
and examined 5-HT2A receptor phosphorylation in various
brain regions known to express the receptor by immunohis-
tochemisty. A robust immunostaining with the anti-phospho-
Ser280 antibody was only detected in mice treated with DOI,
but not in mice treated with vehicle or lisuride and the highest
signal was found in middle layers of prefrontal cortex, which
are known to express highest receptor densities (19) and
which exhibited the strongest immunoreactive signal with a
commercial antibody recognizing 5-HT2A receptor indepen-
dently of its phosphorylation state (Fig. 2E). As expected and
further supporting the specificity of our antibody for phospho-
Ser280 5-HT2A receptor, no immunoreactive signal was de-
tected in prefrontal cortex of DOI-treated 5-HT2A receptor
knockout mice (Fig. 2E).
Phosphorylation of 5-HT2A Receptors by Hallucinogens is
Protein Kinase C-dependent and Gi/o-independent—We next
searched for consensus motifs of phosphorylation by kinases
in the Ser280 flanking sequence by using two different algo-
rithms: (1) Scansite, which defines scores for phosphorylation
sites according to a matrix based on an oriented peptide
library to determine the optimal substrates of protein kinases
(20), and (2) Group-based Prediction System (GPS, v2.1),
which classifies protein kinases into a hierarchical structure
with four levels and trains its algorithm against the Phos-
phoELM database (21), in order to determine individual false
discovery rate for each kinase (22). GPS found a strong con-
sensus for Akt/protein kinase B (PKB) (5.7/3.8) and ribosomal
S6 kinases (RSKs, 2.0/1.9), whereas Scansite indicated a
strong consensus for phosphorylation by protein kinase C
delta (PKC, score 0.3926, percentile 0.143%) and PKB
(0.5238, 0.341%). Thus, pharmacological inhibitors of PKC
(NPC-15437, 20 M) (23), PKB (GSK690693, 1 M) (24), and
RSKs (SL-0101–1, 10 M) (25) were tested for a potential
effect on DOI-elicited Ser280 phosphorylation. Neither
GSK690693 nor SL-0101–1 had any effect on Ser280 phos-
phorylation in response to DOI, indicating that RSKs and PKB
are not involved in this phosphorylation (Fig. 2C). In contrast,
pretreatment of cells with NPC-15437 strongly decreased
basal Ser280 phosphorylation and abolished the DOI-elicited
response, indicating that Ser280 phosphorylation induced by
hallucinogens was dependent on PKC activity (Fig. 2C). More-
over, treatment of cells with PTX did not affect Ser280 phos-
phorylation elicited by DOI (Fig. 2D).
Hallucinogenic and Nonhallucinogenic Agonists Differen-
tially Desensitize and Internalize the 5-HT2A Receptor—Given
the role of PKC in 5-HT2A receptor desensitization and inter-
nalization and the importance of the 5-HT2A receptor i3 loop in
the regulation of receptor responsiveness (26–29), we next
examined whether hallucinogenic and nonhallucinogenic ago-
nists differentially modulate receptor desensitization. Pre-
treatment of HEK-293 cells with either lisuride or ergotamine
for 1 h, followed by extensive drug washout, inhibited inositol
phosphate production induced by a further exposure of cells
to 5-HT, whereas pretreating cells with DOI or LSD did not
significantly affect the 5-HT response (Figs. 3A and 3B). The
most pronounced difference in receptor desensitization (non-
significant desensitization upon hallucinogen stimulation ver-
sus 50% desensitization upon receptor stimulation by non-
hallucinogenic agonists) was observed after a 1 h treatment.
After a 2 h treatment, both DOI and LSD desensitized the
receptor, though to a differing extent (26  4% desensitiza-
tion) when compared with cells exposed for 2 h with lusuride
or ergotamine (61  5% desensitization). Therefore, 1 h pre-
exposures to drugs were undertaken in further experiments.
Treatment of HEK-293 cells with ergotamine and lisuride, but
not with LSD and DOI, likewise induced strong desensitization
of 5-HT2A receptor-operated Erk1,2 signaling (Fig. 3C). Hal-
lucinogenic and nonhallucinogenic agonists produced a sim-
TABLE I
List of phosphorylated peptides identified from purified 5-HT2A receptors by nano-LC-MS/MS. HEK-293 cells transiently expressing
HA-tagged 5-HT2A receptors were exposed to either Vehicle or DOI or LSD or lisuride or ergotamine (1 M each, 15 min). Solubilized receptors
were immunoprecipitated with the anti HA antibody, resolved by SDS-PAGE and digested in-gel with trypsin. Peptides were analyzed by
nano-LC-MS/MS using multistage activation on the neutral loss of phosphoric acid. MS/MS spectra were manually interpreted. For each
peptide, the position of modified residue(s), the position in the protein sequence, experimental mass/charge, theoretical mass, mass deviation,
Mascot score, and relative abundance compared with the non-phosphorylated peptide (site occupancy index: maximal intensity observed in
the phosphorylated peptide extracted ion chromatogram/sum of the maximal intensities observed in the phosphorylated and the nonphos-
phorylated peptide extracted ion chromatograms) are indicated. The data are representative of three independent experiments. ND: not
determined
Modified sequence Start-end Expm/z (Th) Mass (Da)
 mass
(ppm)
Mascot
score
Phosphorylation site occupancy index
Vehicle LSD DOI Lisuride Ergo
K.LAsFSFLPQSSLSSEK.L  Phospho (ST) 278–293 904.4283 1806.8441 	1.11 44 0.327 13.286 20.727 1.304 0.842
K.LAsFSFLPQSSLSsEKLFQR.S  2 Phospho (ST) 278–297 811.3806 2431.1226 	1.05 40 0.076 1.223 1.793 0.318 0.277
K.LAsFSFLPQSSLsSEKLFQR.S  2 Phospho (ST) 278–297 811.3813 2431.1226 	0.23 25 0.076 1.223 1.793 0.318 0.277
K.LAsFSFLPQSSLSsEKLFQR.S  3 Phospho (ST) 278–297 838.035 2511.0889 	2.22 21 ND 0.173 0.229 0.085 0.110
R.sIHREPGSYTGR.R  Phospho (ST) 298–309 480.5517 1438.6354 	1.6 80 0.104 0.280 0.252 0.308 0.230
R.SIHREPGsYTGR.R  Phospho (ST) 298–309 480.5522 1438.6354 	0.5 19 0.104 0.280 0.252 0.308 0.230
R.sIHREPGsYTGRR.T  2 Phospho (ST) 298–310 559.2409 1674.7028 	1.18 20 0.117 0.309 0.357 0.407 0.530
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ilar differential pattern of desensitization at 5-HT2A receptor-
transduced signaling in primary cultures of cortical neurons
(Figs. 3D and 3E).
As GPCR internalization is often important for desensitiza-
tion, we also explored whether hallucinogenic and nonhallu-
cinogenic agonists differentially affect receptor internalization
by immunostaining cell-surface receptors in living cells before
a 1 h exposure to a hallucinogenic or a nonhallucinogenic
agonist. The proportion of internalized 5-HT2A receptors was
much higher in cells treated with lisuride or ergotamine com-
pared with cells exposed to DOI or LSD (Fig. 4A). The higher
propensity of nonhallucinogenic agonists to internalize the
receptor, compared with hallucinogens, was further con-
firmed by ELISA (Fig. 4B). Given the importance of the recep-
tor i3 loop in its association with -arrestins (30), we also
compared the ability of the two agonist categories to promote
-arrestin2 recruitment by the receptor. 5-HT2A receptors
recruited larger amounts of -arrestin2 in cells treated ergot-
FIG. 2. Validation of the differential phosphorylation of Ser280 by hallucinogenic and nonhallucinogenic 5-HT2A agonists using a
phosphosite antibody. A-B, An antibody raised against the GTRAKLApSFSFLC peptide was validated in HEK-293 cells transiently
expressing HA-5-HT2A receptors. Receptors were immunoprecipitated with the agarose bead-conjugated anti HA antibody. The generated
antibody provided an immunoreactive signal in Western blots from cells expressing HA-5-HT2A receptors at a molecular weight corresponding
to the signal obtained with the anti-HA antibody. This immunoreactive signal increased when cells were treated for 15 min with LSD or DOI but
not with lisuride or ergotamine (1 M each). Moreover, the signal was strongly attenuated in cells expressing Ser280A receptors (exposed or not
to DOI), compared with cells expressing the wild type (WT) receptor. C-D, Impact of a 30-min cell pretreatment with NPC-15437 (20 M, PKC
inhibitor), or GSK690693 (1 M, PKB inhibitor) or SL-0101–1 (10 M, RSK inhibitor) and of a 18 h treatment with PTX (0.2 g/ml) upon
DOI-elicited Ser280 phosphorylation. Representative immunoblots of three independent experiments performed on different sets of cultured
cells are illustrated. E, Immunofluorescence detection of cells positive for phospho-Ser280 5-HT2A receptor or 5-HT2A receptor in the prefrontal
cortex of wild type and 5-HT2A receptor-deficient mice (four mice analyzed per condition) injected intraperitoneally with either vehicle or DOI
or lisuride (10 mg/kg, intraperitoneal). Scale bar: 40 m.
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amine or lisuride than in cells exposed to LSD or DOI (Fig. 5C),
corroborating their differential efficacy to promote receptor
internalization.
Ser280 Phosphorylation Underlies Differential Desensitiza-
tion of the 5-HT2A Receptor by Hallucinogenic and Nonhallu-
cinogenic Agonists—To directly determine the pertinence of
Ser280 phosphorylation upon 5HT2A receptor desensitization,
this residue was mutated into alanine or aspartate to inhibit or
mimic its phosphorylation, respectively. Wild type, S280A and
S280D 5-HT2A receptors displayed the same intrinsic efficacy
in stimulating PLC and Erk1,2 upon activation by 5-HT (Figs.
5A and 5B). Nonetheless, the differential ability of hallucino-
genic and nonhallucinogenic agonists to desensitize the re-
ceptor was not observed in cells expressing S280A or S280D
5-HT2A receptors: hallucinogenic as well as nonhallucino-
genic agonists induced a strong desensitization of both PLC
and Erk1,2 signaling in cells expressing the S280A receptor (to
an extent comparable with that measured in cells expressing
the wild type receptor after ergotamine or lisuride pretreat-
ment), whereas all the four agonists tested induced a weak
desensitization of receptor-operated signaling in cells ex-
pressing S280D 5-HT2A receptor, as observed in cells ex-
pressing wild type receptors following treatment with DOI or
LSD (Figs. 5B and 5C).
DISCUSSION
The concept of functional selectivity or biased agonism was
initially thought to reflect the ability of specific ligands of a
FIG. 3. Hallucinogenic and nonhallu-
cinogenic agonists differentially de-
sensitize 5-HT2A receptors. A, Schema
of the experimental paradigm used to
investigate the desensitization of 5-HT2A
receptor induced by hallucinogenic and
nonhallucinogenic agonists in HEK-293
cells and neurons. B and D, Effect of a
1 h pretreatment with either DOI or LSD
or lisuride or ergotamine (1 M each)
upon inositol phosphate production elic-
ited by 5-HT (10 M) in HEK-293 cells (B)
and neurons (D). Data, expressed in% of
the 5-HT-elicited response in cells pre-
treated with vehicle are the means 
S.E. of values obtained in three inde-
pendent experiments performed on
different sets of cultured cells. * p 0.05
versus vehicle-pretreated cells (ANOVA
followed by Dunnett’s test). C and E,
Effects of the corresponding treatments
upon 5-HT-elicited Erk1,2 phosphoryla-
tion, assessed by sequential immuno-
blotting with an antibody against phos-
phorylated Erk1,2 (Thr202-Tyr204) and an
antibody recognizing Erk1,2 indepen-
dently of their phosphorylation state. Im-
munoblots representative of three inde-
pendent experiments are shown. Data,
expressed as ratios of phosphorylated to
total Erk1,2, represent the means  S.E.
of values obtained in the three indepen-
dent experiments. * p 0.05, ** p 0.01
versus cells pretreated with vehicle.
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given GPCR to induce or stabilize different active conforma-
tions capable of activating distinct signaling pathways (31–
33). The difference in 5-HT2A receptor-operated signaling
upon activation by hallucinogenic and nonhallucinogenic ago-
nists represents one of the most remarkable examples of
functional selectivity so far characterized (9). More recently,
phosphorylation of GPCRs at specific sites has emerged as
one mechanisms contributing to functional selectivity (34) and
several studies have revealed the capacity of different ligands
of a given receptor to promote preferential receptor phosphor-
ylation at distinct sites (35–38). The present report likewise
demonstrated the ability of a subset of 5-HT2A receptor ago-
FIG. 4. Hallucinogenic and nonhallucinogenic agonists differentially internalize 5-HT2A receptors. A, HEK-293 cells transiently ex-
pressing HA-tagged 5-HT2A receptors were treated for 30 min at 10 °C with a rabbit anti HA antibody and then with either vehicle or DOI or
LSD or lisuride or ergotamine (1 M each) for 1 h at 37 °C. Cell surface receptors were labeled with the Alexa Fluor® 594-coupled anti-HA
antibody (red channel) and internalized receptor with the Alexa Fluor® 488-coupled anti-HA antibody (green channel). Double immunofluo-
rescence staining of receptors in single cells is shown. Representative images of three independent experiments are illustrated. B, Quantifi-
cation of cell surface expression of receptors in cells exposed to the same treatments was performed by ELISA in nonpermeabilizing
conditions. Data are means  S.E. of quadruplicate determinations performed in a representative experiment. Two other independent
experiments yielded similar results. * p  0.05 versus vehicle-treated cells (ANOVA followed by Dunnett’s test). C, The data illustrated show
the differential recruitment of -arrestin2 by the 5-HT2A receptor (assessed by co-immunoprecipitation) in cells co-expressing HA-tagged
5-HT2A receptor and YFP-tagged -arrestin2 and exposed to the same treatments. The Western blots illustrated are representative of three
independent experiments.
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nists to induce phosphorylation of one well-defined site, de-
spite a similar intrinsic efficacy to transduce signals. Biased
5-HT2A receptor phosphorylation elicited by the different ago-
nists tested correlated with their behavioral outcomes and
might represent one critical step underlying functional selec-
tivity at these receptors.
Mass spectrometry analyses identified several phosphory-
lated forms of the same peptide located in the receptor i3 loop
(LASFSFIPQSSISSEK). These included a unique monophos-
phorylated form (phosphorylated at Ser280), and several less
abundant doubly or triply phosphorylated forms systemati-
cally phosphorylated at Ser280. All these phosphorylated pep-
tides were up-regulated by hallucinogens but not by nonhal-
lucinogenic agonists. Collectively, these observations clearly
identify Ser280 phosphorylation as the primary event govern-
ing further phosphorylation of downstream serine residues.
Differential phosphorylation of Ser280 upon receptor activation
by hallucinogenic and nonhallucinogenic agonists was further
established in vivo following systemic administration of these
compounds to mice, by using a phosphosite specific anti-
body. Further supporting the relevance of Ser280 phosphory-
lation, the most prominent phospho-Ser280 immunoreactive
signal in mice treated with a hallucinogenic agonist was de-
tected in prefrontal cortex, the brain region involved in the
psychomimetic effects of hallucinogens (8).
We identified another cluster of phosphorylated serines
(Ser298 and Ser305) in a receptor i3 loop peptide (SIHREPG-
SYTGR). Both monophosphorylated (at Ser298) and doubly
phosphorylated forms of this peptide were detected in the
present study, in contrast with a previous large-scale analysis
of synapse phosphoproteome in the mouse, which only iden-
tified phosphorylated Ser298 (39). The phosphorylation of
Ser298 and Ser305 was weakly induced by both hallucinogens
and nonhallucinogenic agonists. Moreover, our studies did
not detect phosphorylation of Ser314, another serine located
in the receptor i3 loop previously identified as a RSK2 sub-
strate (26). Notably, phosphorylation of this residue was de-
tected in vitro by incubating receptor i3 loop or the entire
purified 5-HT2A receptor with recombinant RSK2, whereas the
present study investigated the receptor phosphorylation state
in HEK-293 cells. Further experiments suggested a role of
Ser314 phosphorylation in attenuation of 5-HT2A receptor sig-
naling induced by EGF and PDGF in a variety of cell types,
including neurons (40). Our results suggest that in the ab-
sence of growth factors, Ser314 phosphorylation might occur
at a lower stoichiometry than the other phosphorylated resi-
dues identified in the present study, even upon agonist stim-
ulation of 5-HT2A receptors. Together with previous findings,
they also identify the receptor i3 loop, which contains 18
potential phosphorylation sites for Ser/Thr kinases, as a hot
FIG. 5. Ser280 phosphorylation under-
lies differential 5-HT2A receptor desen-
sitization by hallucinogenic and non-
hallucinogenic agonists. A, Inositol
phosphate production induced by incre-
mental concentrations of 5-HT in HEK-
293 cells transiently expressing wild type
or S280A or S280D 5-HT2A receptors. Data,
expressed in % of the maximal 5-HT re-
sponse in cells expressing wild type re-
ceptors are the means  S.E. of quadru-
plicate determinations performed in a
typical experiment. Two other experi-
ments performed on different sets of cul-
tured cells yielded similar results. B, Effect
of a 1 h pretreatment with either vehicle
(Veh) or DOI or LSD or lisuride or ergota-
mine (1 M each) upon ERK1,2 phosphor-
ylation elicited by 5-HT (10 M) in HEK-
293 cells expressing wild type or S280A or
S280D 5-HT2A receptors. Immunoblots
representative of three independent ex-
periments are shown. C, Effect of the
corresponding treatments upon inositol
phosphate production elicited by 5-HT
(10 M) in HEK-293 cells expressing wild
type or S280A or S280D 5-HT2A receptors.
Data, expressed in % of the 5-HT-elicited
response in cells pretreated with vehicle,
are the means  S.E. of values obtained
in three independent experiments. * p 
0.05 versus vehicle-pretreated cells
(ANOVA followed by Dunnett’s test).
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spot of phosphorylation potentially important for regulating
receptor functional activity.
In an effort to identify protein kinase(s) contributing to hal-
lucinogen-elicited Ser280 phosphorylation, we found that it
was dependent on PKC activity, though we cannot conclude
at this stage whether PKC directly phosphorylates Ser280 or
whether the phosphorylation of this residue is elicited by a
closely related kinase different from RSK and PKB and acti-
vated by PKC. This observation was quite unexpected as both
hallucinogenic and nonhallucinogenic agonists activate the
PLC pathway and therefore PKC. Moreover, PTX treatment
did not affect DOI-elicited Ser280 phosphorylation, indicating
that biased 5-HT2A receptor phosphorylation is not triggered
by a pathway (Gi/o-dependent) selectively engaged by hallu-
cinogens but rather by a common pathway activated by both
hallucinogenic and hallucinogenic agonists. We thus hypoth-
esize that Ser280 might be accessible for PKC phosphoryla-
tion only in a 5-HT2A receptor conformation that is specifically
stabilized by hallucinogens.
Another important finding of the present study is the differ-
ent ability of hallucinogenic and nonhallucinogenic agonists to
induce 5-HT2A receptor desensitization and internalization,
observed in both HEK-293 cells and cortical neurons. To our
knowledge, no study has so far compared the ability of hal-
lucinogenic and nonhallucinogenic compounds to desensitize
5-HT2A receptors. Nonetheless, the present findings are con-
sistent with a recent study, which demonstrated that DOI was
less efficient than 5-HT to internalize eGFP-tagged 5-HT2A
receptors stably expressed in HEK-293 cells (27). They also
provide convergent evidence indicating that the different ef-
fects of hallucinogenic versus non hallucinogenic agonists
upon receptor desensitization reflect their differential capacity
to promote Ser280 phosphorylation: (1) mutating Ser280 into
alanine or aspartate abolished the difference in the agonist
effects upon receptor desensitization; (2) hallucinogens were
able to desensitize S280A receptor to an extent comparable to
that induced by nonhallucinogenic agonists in cells express-
ing wild type receptor and (3) nonhallucinogenic agonists did
not promote desensitization of the Ser280D receptor mutant.
Collectively, these observations establish a direct link be-
tween Ser280 phosphorylation and the low capacity of hallu-
cinogens to desensitize the receptor and suggest that Ser280
is phosphorylated at a high stoichiometry following hallucino-
gen treatment. These findings contrast with a previous study
which showed that mutating into alanine two serine residues,
one (Ser421) located in the receptor C terminus and the other
(Ser188) in the i2 loop, strongly reduced quipazine-mediated
receptor desensitization, whereas the deletion of residues
280–296 or residues 280–310 in the i3 loop (i.e. Ser280 and
downstream residues phosphorylated upon hallucinogen
treatment) had no effect on the time course and extent of
5-HT2A receptor desensitization (41). However, it is likely that
the agonist used to induce receptor desensitization (quipa-
zine), which is devoid of hallucinogenic activity in humans
(42), does not induce S280 phosphorylation, like lisuride and
ergotamine. Phosphorylation of other residues (e.g. Ser188
and/or Ser421), though not detected in our MS/MS analyses,
might thus underlie 5-HT2A receptor desensitization induced
by any receptor agonist, whereas the specific phosphoryla-
tion of Ser280 (and/or of downstream serines in i3 loop) by
hallucinogens might act as a brake limiting receptor desensi-
tization. Alternatively, Ser280 phosphorylation might facilitate
5-HT2A receptor resensitization that occurs in the continuous
presence of agonist, consistent with previous findings indi-
cating that receptor resensitization, like Ser280 phosphoryla-
tion, is also dependent of PKC (28).
Initial studies on 5-HT2A receptor desensitization and inter-
nalization showed that they are both -arrestin-independent
(43), contrasting with what is more generally observed for
numerous GPCRs. However, the situation is probably more
complex than previously imagined, as a more recent study
revealed a differential pattern of -arrestin sensitivity for ag-
onist-induced receptor internalization: though treatment with
DOI or the 5-HT precursor L-5-hydroxy-tryptophan displayed
similar efficacies to promote receptor internalization, DOI-
induced receptor internalization was -arrestin-independent,
whereas 5-HT-induced internalization requires -arrestins
(44). -arrestin-independent receptor internalization elicited
by DOI treatment corroborates with the low ability of this
compound to promote -arrestin recruitment by the receptor
(compared with nonhallucinogenic agonists), a property
shared by LSD and likely reflecting the unique ability of hal-
lucinogens to promote Ser280 phosphorylation. Whether -ar-
restins contributes to receptor-internalization elicited by the
nonhallucinogenic agonists remains to be elucidated.
In conclusion, our observations show that ligand identity
not only determines the nature of 5-HT2A receptor-operated
signaling but also the pattern of receptor phosphorylation at a
site (Ser280) involved in desensitization and internalization.
They highlight the power of quantitative phosphoproteomics
to identify mechanisms underlying functional selectivity and of
potential relevance to the behavioral responses induced by
biased ligands. The clinical significance of the biased 5-HT2A
receptor phosphorylation remains to be established. In this
regard, it would be of considerable interest to explore in
future studies how Ser280 phosphorylation is affected by the
different classes of antipsychotics and by 5-HT2A receptor
heterodimerization with mGlu2 metabotropic glutamate re-
ceptor, a process critical for hallucinogen psychomimetic
activity (45, 46).
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